

## **2003 FDA/Industry Statistics Workshop**

*Sponsored by the ASA Biopharmaceutical Section and the FDA Statistical Association*

*“STATISTICS: FROM THEORY TO REGULATORY ACCEPTANCE”*

**September 18–19, 2003**

**Hyatt Regency Bethesda — Bethesda, Maryland**

## 2003 FDA/INDUSTRY WORKSHOP ORGANIZING COMMITTEE

Co-Chairs: Ed Nevius - FDA/CDER  
Wasima Rida - Statistics Collaborative  
Corsee Sanders - Genentech, Inc



Charles Anello - FDA/CDER  
Alex Bajamonde - Genentech, Inc  
Christopher Barker - MEDTAP International, Inc.  
Pilar Lim - Johnson & Johnson Pharmaceutical  
Karl Lin - FDA/CDER  
Gary Littman - Wyeth Research  
Stella Machado - FDA/CDER  
Devan Mehrotra - Merck Research Laboratories  
Catherine Melfi - Eli Lilly and Company  
Greg Campbell - FDA/CDER  
Michelle Capozzoli - Framingham State College  
Aloka Chakravarty - FDA/CDER  
George Chi - FDA/CDER  
Randy Davis - GlaxoSmithKline  
Art DeVault - Roche Molecular Systems, Inc.  
Mary Foulkes - FDA/CBER  
Davis Gates, Jr. - Schering- Plough Research Institute  
Anna Nevius - FDA/CVM  
Gene Pennello - FDA/CDRH  
Kim Perry - Pfizer  
David Radley - Merck Research Laboratories  
Todd Sahlroot - FDA/CDER  
Amrik Shah - Schering Plough Research Institute  
Lakshmi Vishnuvajjala - FDA/CDRH  
Sue-Jane Wang - FDA/CDER  
Stephen Wilson - FDA/CDER  
Ronald Helms - Rho, Inc.  
Lee Kaiser - Genentech, Inc.  
Karen Kesler - Rho, Inc.  
John Lawrence - FDA/CDER  
Janet Wittes - Statistics Collaborative

# 2003 FDA/Industry Statistics Workshop

September 18-19 • Bethesda Hyatt • Bethesda, Maryland

*“Statistics: From Theory to Regulatory Acceptance”*

Sponsored by the Biopharmaceutical Section of the American Statistical Association in collaboration with the Food and Drug Administration Statistical Association, this workshop provides an opportunity to exchange views with a broad range of individuals from regulatory agencies, the pharmaceutical and biotech industry, academia, and others interested in drug, biologics, and medical device development.

## LOCATION:

The workshop will be held at the Hyatt Regency Bethesda, conveniently located on the Metro red line just six miles from downtown Washington, DC.

## REGISTRATION:

On-line registration at <http://www.amstat.org/meetings/fdaworkshop>. For further information, contact ASA Meetings Department, 1429 Duke Street, Alexandria, VA 22314, telephone (703) 684-1221 ext. 145, fax (703) 684-8069, email: [meetings@amstat.org](mailto:meetings@amstat.org).

## HOTEL RESERVATION:

Hotel rooms at the Hyatt Regency Bethesda are available at the single or double rate of \$185 per night plus 12% lodging tax. Early arrivals or late departures can inquire about extension of the rate. The conference rate and availability cannot be guaranteed after August 22, 2003. Call toll free 1-800-633-7313 in the U.S. and Canada. Locally, call (301) 657-1234 or fax (301) 657-6453.

## Wednesday September 17, 2003

### 1:00pm Short Courses (Limited to 60 Participants per Course)

- A. **Handling Missing Data in Longitudinal Studies**—Ronald Helms (Rho, Inc.)
- B. **Active Control Non-Inferiority Trials**—George Chi (FDA) and Gang Chen (Johnson & Johnson)

5:00pm Adjourn for the day

## Thursday September 18, 2003

7:30am Continental Breakfast

8:30am Welcome—Corsee Sanders (Genentech), Wasima Rida (Statistics Collaborative), Ed Nevius (FDA)

### 8:45am Plenary Session I: Flexible Designs

Chairs: Ronald Helms (Rho, Inc.), Randy Davis (GlaxoSmithKline), and Sue-Jane Wang (FDA)

1. “Select the Winner in Drug Development”—Gordon Lan (Aventis Pharmaceuticals)
2. “Use of Bayesian Modeling and Simulation for Design and Analysis of Clinical Trials”—Bill Gillespie (Pharsight)
3. “Adaptation of Clinical Trial Design and Inference”—James Hung (FDA)


10:15am Break


### 10:45am Plenary Session II: Longitudinal Data Analysis—Issues and Recommendations

Chairs: Devan Mehrotra (Merck) and Anna Nevius (FDA)

1. “Handling Incomplete Data in Clinical Studies”—Geert Molenberghs (Limburgs Universitair Centrum Belgium)
2. “Considerations Regarding Choice of the Primary Analysis in Longitudinal Trials with Dropouts: An FDA Perspective”—Bob O’Neill (FDA)
3. Discussant—Tom Louis (Johns Hopkins University)

12:15pm Lunch on your own





**1:30pm Plenary Session III: Trial Monitoring**

Chairs: Pilar Lim (Johnson & Johnson) and Greg Campbell (FDA)

1. "On the Superiority of Adaptive Designs"—Qing Liu (Johnson & Johnson) and Gordon Pledger (Johnson & Johnson)
2. "Changing Trial Design on the Fly"—Janet Wittes (Statistics Collaborative)
3. "Interim Analysis in Clinical Trials: A Bayesian Approach in the Regulatory Setting"—Telba Irony (FDA) and Gene Pennello (FDA)
4. Discussant—Keaven Anderson (Centocor)

**3:00pm** Break

**3:30pm Plenary Session IV: Perspectives on Safety Issues in Drug Development**

Chair: Cathy Melfi (Eli Lilly) and Aloka Chakravarty (FDA)

1. "Perspectives of Safety Issues in Drug Development-Industry Statistical Perspective"—Tim Costigan (Eli Lilly)
2. Academic Perspective—Carol Redmond (University of Pittsburgh)
3. FDA Perspective—George Rochester (FDA)

**5:00pm** Reception at Fellini's

**Friday September 19, 2003**

**7:30am** Continental Breakfast

**8:30am Parallel Sessions I**

**A. Time to Event Data**

Chairs: Davis Gates (Schering-Plough) and Gene Pennello (FDA)

1. "An Efficient Alternative to the Cox Model for Small Time-to-Event Trials"—Devan Mehrotra (Merck)
2. "Issues in the Analysis of Failure Time Data"—Rebecca Betensky (Harvard School of Public Health)
3. Panel Discussion—Tony Lachenbruch (FDA), James Hung (FDA), Devan Mehrotra (Merck), and Rebecca Betensky (Harvard School of Public Health)

**B. Multinational Trials**

Chairs: Janet Wittes (Statistics Collaborative) and John Lawrence (FDA)

1. "Delivering Robust Outcomes from Multinational Trials: Principles and Strategies"—Andreas Sashegyi (Eli Lilly)
2. "Considerations for the Choice and Interpretation of Endpoints in International Trials of Antiretroviral Therapies"—Victor DeGruttola (Harvard School of Public Health)
3. "Multi-Clinic and Multi-National Trials: A Regulatory Perspective"—Charles Anello (FDA)

**C. Genomics in Drug Discovery and Development**

Chairs: Michelle Capozzoli (Framingham State) and Sue-Jane Wang (FDA)

1. "Complex Adaptive Systems and Human Health: Statistical Approaches in Pharmacogenomics"—Kim Zerba (Bristol-Myers-Squibb)
2. "Sample Size Selection for Gene Expression Studies"—Greg Warnes (Pfizer, Inc.)
3. "Cross-Study Validation of Molecular Classification in Cancer"—Giovanni Parmigiani (Johns Hopkins University)
4. "Selection of Differential Expression Genes in Microarray Experiment"—James Chen (FDA)

**10:15am** Break

**10:30am Parallel Sessions II**

**A. Analysis Databases**

Chairs: Ronald Helms (Rho, Inc.) and Steve Wilson (FDA)

1. Industry Perspective—Russ Helms (Rho, Inc.)
2. Academic Perspective—Dave Christiansen (Christiansen Consulting)
3. "A Regulatory Perspective"—Steve Wilson (FDA)

## **B. Post-Marketing Issues**

Chairs: David Radley (Merck) and Charles Anello (FDA)

1. "Perspectives on Automated Methods for Pharmacovigilance Signal Detection"  
—Larry Gould (Merck)
2. "Rapid Cycle Analysis of Vaccine Safety"—Bob Davis (University of Washington)
3. FDA Perspective—David Graham (FDA)

## **C. Preclinical and Early Clinical Data**

Chairs: Amrik Shah (Schering-Plough) and Karl Lin (FDA)

1. "Evaluation of Live Phase Results from Carcinogenicity Studies"—Wherly Hoffman (Eli Lilly)
2. "Peto Trend Test: Investigating the Impact of Tumor Misclassification"—Amrik Shah (Schering-Plough) and Melody Goodman (Harvard School of Public Health)
3. "Statistical Issues in Review of Carcinogenicity Studies Using Transgenic Mice"—Karl Lin (FDA) and Feng Zhou (FDA)

**12:15pm** Lunch on your own

## **1:30pm Parallel Sessions III**

### **A. Randomization—Uses and Abuses**

Chairs: Alex Bajamonde (Genentech) and Todd Sahlroot (FDA)

1. "Uses and Abuses of (Adaptive) Randomization: an Industry Perspective"  
—Benjamin Lyons (Johnson & Johnson) and Akiko Okamoto (Johnson & Johnson)
2. "Maximizing Power and Minimizing Treatment Failures Using Randomization"  
—William Rosenberger (University of Maryland at Baltimore County)
3. "Computer Intensive and Re-randomization Tests in Clinical Trials"  
—Tom Hammerstrom (FDA)

### **B. Diagnostic Evaluation**

Chairs: Lee Kaiser (Genentech) and Lakshmi Vishnuvajjala (FDA)

1. "Methods Comparison Studies for Quantitative Nucleic Acid Assays" —Jacqueline Law (Roche Molecular Systems) and Art DeVault (Roche Molecular Systems)
2. "A Cautionary Note on the Robustness of Latent Class Models for Estimating Diagnostic Error without a Gold Standard"—Paul Albert (NCI) and Lori Dodd (NCI)
3. "Propensity Scores Methodology for Receiver Operating Characteristic (ROC) Analysis"—Marina Kondratovich (FDA)

### **C. Getting the Dose Right**

Chairs: Gary Littman (Wyeth) and Stella Machado (FDA)

1. "Dose Spacing in Early Dose Response Clinical Trial Designs"- Naitee Ting (Pfizer)
2. "Adaptive Dose Selection: Getting the Most Out of What You Currently Know"  
—Andy Grieve (Pfizer and the University of Kent, UK)
3. "Risk and Benefit Assessments for Optimal Dose Selection Based on Exposure Response" —Peter Lee (FDA)

**3:15pm** Break

## **3:30pm Special Interest Sessions**

### **A. Surrogate Endpoints in Vaccine Efficacy Trials**

Chairs: Devan Mehrotra (Merck), Janet Wittes (Statistics Collaborative), and Sang Ahnn (FDA)

1. "Licensing a Vaccine on the Basis of Surrogate Endpoints: A Practical Example"  
—Robert Kohberger (Wyeth)
2. "On the Use of Surrogate Endpoints in HIV Vaccine Efficacy Trials" Steve Self (Fred Hutchinson Cancer Research Center)
3. FDA perspective

### **B. Statistical Methods in Advisory Panel Meetings**

Chair: Mary Foulkes (FDA)

1. Joe Verter (Statistics Collaborative)
2. Greg Enas (Eli Lilly)

### **C. Statistical Issues in Medical Devices**

Chair: Greg Campbell (FDA)

1. William C. Blackwelder (Biologics Consulting Group)
2. Frank Hurley (HD Consulting)
3. Lakshmi Vishnuvajjala (FDA)

**5:00pm** Adjourn



# 2003 BIOPHARMACEUTICAL SECTION CORPORATE SPONSORS

Allergan  
Amgen  
Astra Zeneca  
Aventis  
Bristol-Myers Squibb  
Centocor  
Genentech  
Genzyme  
GlaxoSmithKline  
Johnson & Johnson  
Merck  
Novartis  
Pfizer  
Purdue Pharma  
Sanofi-Synthelabo  
SAS Institute  
Schering-Plough  
Wyeth  
3M Pharmaceuticals